Drug
Rmc 6236
Rmc 6236: highest development phase Phase 3, developed by Revolution Medicines. 3 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Revolution Medicines
Trials
| Drug | Phase | Indication |
|---|---|---|
| RMC-6236 NCT06625320 | Phase 3 | Pancreatic Cancer |
| RMC-6236 NCT06445062 | Phase 1/2 | Colorectal Cancer |
| RMC-6236 NCT05379985 | Phase 1/2 | Non-small Cell Lung Cancer (NSCLC) |
Latest
No recent events.
Follow Rmc 6236 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.